[Zantac (ranitidine) in treating duodenal ulcers]

Area of Science:

• Gastroenterology
• Microbiology
• Pharmacology

Background:

• Duodenal ulcers are common gastrointestinal conditions.
• Helicobacter pylori (HP) infection is a major causative factor in duodenal ulcer disease.
• Effective treatment strategies are crucial for ulcer healing and preventing recurrence.

Purpose of the Study:

• To evaluate the efficacy of a combination therapy for duodenal ulcers in HP-positive patients.
• To compare the treatment outcomes between HP-positive and HP-negative patients with duodenal ulcers.
• To assess the eradication rates of Helicobacter pylori following treatment.

Main Methods:

• A study involving 68 patients diagnosed with duodenal ulcers.
• HP infection identified through histological examination and/or rapid urease testing.
• Treatment involved a four-week course of ranitidine, with amoxicillin and metronidazole added for the first ten days in HP-positive patients.
• Ulcer healing assessed after four weeks of treatment.
• HP eradication confirmed 28-42 days post-treatment.

Main Results:

• Duodenal ulcer healing observed in 82.7% of HP-positive patients receiving combination therapy.
• Ulcer healing occurred in 81.3% of HP-negative patients treated with ranitidine alone.
• Successful eradication of HP was achieved in 86.5% of the treated HP-positive patients.

Conclusions:

• Combination therapy including ranitidine, amoxicillin, and metronidazole is effective for treating duodenal ulcers in HP-positive individuals.
• Ranitidine monotherapy shows comparable healing rates in HP-negative patients.
• The treatment regimen effectively eradicates Helicobacter pylori, contributing to ulcer healing.